
RET-He-guided IV iron used less iron while remaining noninferior for erythropoietin resistance in hemodialysis
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
In a multicenter randomized noninferiority trial of 160 hemodialysis patients, reticulocyte hemoglobin equivalent-guided intravenous iron was noninferior to transferrin saturation-guided dosing for erythropoietin resistance at three and six months and used less cumulative iron.
What NurseJet pulled from the source
The trial randomized 79 patients to a transferrin saturation-guided protocol and 81 to a reticulocyte hemoglobin equivalent, or RET-He, protocol. RET-He guidance met the prespecified noninferiority threshold for the erythropoietin resistance index at both three and six months and resulted in a significantly lower cumulative intravenous iron dose. Mortality, hospitalization, cardiovascular events, transfusion, and infection did not differ significantly, but the study was not powered to establish differences in those clinical outcomes.
Why this matters for nurses
Dialysis and medical-surgical nurses administer intravenous iron, trend anemia-related laboratory data, monitor treatment tolerance, and coordinate erythropoiesis-stimulating therapy. The trial evaluates a potentially more accessible dosing marker while keeping the evidence boundary focused on a protocol-level surrogate outcome.
Bedside takeaway
RET-He-guided dosing reduced cumulative IV iron without worsening the studied resistance index, but clinical safety equivalence remains unproven.
How This Applies in Practice
Use this when: Administering intravenous iron within a nephrology-approved anemia protocol for a patient receiving maintenance hemodialysis.
On your shift
- Verify the protocol-specified laboratory marker, result date, prescribed dose, vascular access, and recent iron and erythropoiesis-stimulating therapy before administration.
- Monitor for infusion reactions and changes in infection status or fluid tolerance, and stop or escalate according to the dialysis medication pathway.
- Trend cumulative iron exposure and anemia-related results and communicate unexpected or discordant patterns to the nephrology team.
Explain this for my unit
Key takeaways
- The multicenter trial randomized 160 hemodialysis patients to RET-He-guided or transferrin saturation-guided intravenous iron protocols.
- RET-He guidance was noninferior for the erythropoietin resistance index at three and six months.
- Patients in the RET-He group received a significantly lower cumulative intravenous iron dose.
- The trial was not powered to determine differences in mortality, hospitalization, cardiovascular events, transfusion, or infection.
Practice implications
- Use only the ordered dialysis anemia protocol, verify current laboratory results and the prescribed iron dose, and monitor for infusion reactions or signs of infection and overload. Document cumulative therapy and communicate discordant laboratory trends or changes in clinical status to the nephrology team.
Limitations & cautions
- The primary outcome was the erythropoietin resistance index rather than a patient-centered clinical endpoint. The sample of 160 patients and six-month follow-up were insufficient to compare uncommon safety events, hospitalization, cardiovascular outcomes, transfusion, infection, or mortality, so noninferiority should not be extended to those outcomes.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
Nephrology (Carlton, Vic.) (PubMed)
Nephrology (Carlton, Vic.) (PubMed). Efficacy of Reticulocyte Haemoglobin Equivalent-Guided Versus Transferrin Saturation-Guided Iron Supplement Protocol in Haemodialysis Patients: A Multicenter Cluster Randomized Controlled Trial.
https://pubmed.ncbi.nlm.nih.gov/42477910/
Professional education only


